Global Bacteriophages Therapy Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Aug 2021
  • Global
  • 350 Pages
  • No of Tables: 315
  • No of Figures: 77

Global Bacteriophages Therapy Market, By Target (Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, Others), Type (Lytic, Lysogenic), Base (Sterile Broth Culture, Water-Soluble Jelly Base), Application (Bacterial Dysentery, Infections Of Skin And Nasal Mucosa, Suppurative Skin Infection, Lung And Pleural Infections, Postoperative Wound Infections, Others), Route Of Administration (Oral, Parenteral, Rectal, Dermal, Others), End User (Hospitals, Speciality Clinics, Academic Research And Institutes, Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest Of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest Of Asia-Pacific, Brazil, Argentina, Peru, Rest Of South America, Saudi Arabia, South Africa, U.A.E, Israel, Kuwait, Egypt  And Rest Of Middle East And Africa) Industry Trends And Forecast To 2028.       

 Bacteriophages Therapy MarketMarket Analysis and Insights: Global Bacteriophages Therapy Market

The global bacteriophages therapy market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.7% in the forecast period of 2021 to 2028 and is expected to reach USD 60.64 million by 2028. The increasing prevalence of antibiotic-resistant infections and increasing research and development activities are the major drivers which are expected to propel the demand of the bacteriophages therapy market in the forecast period.

Bacteriophage, also called phage or bacterial virus, is any group of viruses that infect bacteria to treat bacterial infections. Bacteriophages could be used as an alternative to antibiotics when bacteria develop resistance. Bacteriophages are much more specific than antibiotics. They are typically harmless not only to the host organism but also to other beneficial bacteria, such as the gut microbiota, thereby reducing the chances of opportunistic infections. The presence of novel pipeline drugs, strategic initiatives by market players, and rise in expenditure in the healthcare sector are expected to provide a lucrative growth opportunity for the market.  However, high costs associated with therapy and shortage of skilled professionals are the factors expected to restraint the market growth in the forecast period.

The bacteriophages therapy market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Bacteriophages Therapy MarketGlobal Bacteriophages Therapy Market Scope and Market Size   

The bacteriophages therapy market is segmented on the basis of target, type, base, application, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

  • On the basis of target, the bacteriophages therapy market is segmented into Escherichia coli, staphylococcus, streptococcus, pseudomonas, salmonella, others. In 2021, the staphylococcus segment is expected to dominate the market as this species is the most common bacterial species causing infection and a variety of diseases that need proper treatment for the condition to get cured.
  • On the basis of type, the bacteriophages therapy market is segmented into lytic and lysogenic. In 2021, the lytic segment is expected to dominate the market because of the instant recovery and therapeutic effect provided by lytic bacteriophages.
  • On the basis of the base, the bacteriophages therapy market is segmented into sterile broth culture, water-soluble jelly base. In 2021, sterile broth culture is expected to dominate the market as the bacteriophage is cultured at varying oxygen levels in sterile broth, and more specificity towards the bacteriophages is provided in broth culture.
  • On the basis of application, the bacteriophages therapy market is segmented into bacterial dysentery, infections of the skin and nasal mucosa, suppurative skin infection, lung and pleural infections, post-operative wound infections, others. In 2021, the post-operative wound segment is expected to dominate the market due to the number of open surgeries and accidental cases that take place around the world.
  • On the basis of route of administration, the bacteriophages therapy market is segmented into oral, parenteral, rectal, dermal, others. In 2021, the oral segment is expected to dominate the market due to the rising focus on the development of new administration techniques, out of which oral is the effective and patient convenient route for administration for bacteriophages.
  • On the basis of end-user, the bacteriophages therapy market is segmented into hospitals, specialty clinics, academic research and institutes, others. In 2021, the hospital's segment is expected to dominate the market due to the growing emphasis on bacteriophages therapy, partnerships with various research institutes for clinical trials, and personalized phage therapy for the patients.
  • On the basis of distribution channels, the bacteriophages therapy market is segmented into direct sales and third-party distributors. In 2021, the direct tender segment is expected to dominate the market because of a larger number of players in the market and the geographical presence of these market players.

Bacteriophages Therapy Market Bacteriophages Therapy Market Country Level Analysis

The bacteriophages therapy market is analyzed, and market size information is provided on the basis of target, type, base, application, route of administration, end-user, and distribution channel

The countries covered in the bacteriophages therapy market report are the U.S., Canada, Mexico, Germany, France, U.K., Belgium, Georgia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerland, rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Kuwait, Israel, rest of the Middle East and Africa.  

The North American region is expected to dominate the bacteriophages therapy market and grow with the highest growth rate in the forecast period of 2021 to 2028 because of the immediate recovery and therapeutic effect provided by lytic bacteriophage. Georgia is expected to dominate the bacteriophages therapy market in the lytic segment owing to advancements in phage therapy. China is expected to dominate the bacteriophages therapy market with leading growth in the Asia-Pacific market because of increasing investment in innovative R&D for novel drug products.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Private Sector Funding And Technological Advancements Are Boosting The Market Growth Of Bacteriophages Therapy. 

The bacteriophages therapy market also provides you with detailed market analysis for every country's growth in the bacteriophage therapy industry with drugs sales, the impact of advancement, technology, and changes in regulatory scenarios with their support for the bacteriophages therapy market. The data is available for the historical period 2011 to 2019.

Competitive Landscape and Bacteriophages Therapy Market Share Analysis

Bacteriophages therapy market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the bacteriophages therapy market.

The major companies operating in the global bacteriophages therapy market are Microgen, Micreos, ATCC, Intralytix, Inc., Adaptive Phage Therapeutics, Armata pharmaceuticals Inc., LOCUS BIOSCIENCES, INC., Delmont Laboratories, Inc., Nextbiotics, Pherecydes Pharma, Pylum, iNtODEWORLD, Inc., INC., Enbiotix, Fixed-Phage Limited, and Cytophage Technologies Inc among others.

Many product launches and agreements are also initiated by companies worldwide which are also accelerating the bacteriophage therapy market.

For instance,

  • In April 2020, Phagelux, Inc. announced that the company has entered into multiple commercial collaborations such as European sales, marketing, and product development collaboration with DCM for its AgriPhage line of biopesticides, among others. This has helped the company to explore and develop next generation bacteriophages fully
  • In In July 2020, Intralytix, Inc. announced that the company had received a patent from the U.S. Patent and Trademark Office for its Shigella bacteriophages and its applications. The company further added that the patent covers various areas such as specific uses of these formulations, several bacteriophages with strong lytic potency against Shigella, and their various formulations. This has helped the company to provide protection for a pre-determined period, allowing to keep competitors at bay
  • In June 2021, Adaptive Phage Therapeutics announced the initiation of Phase 1/2 study of bacteriophage therapy (Phage Bank) to evaluate the safety, tolerability, and efficacy of targeted, personalized bacteriophage ("phage") treatments in patients with urinary tract infection (UTI).   This has helped the company to develop a novel treatment for multi multi-drug resistant bacterial infections

Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player are enhancing the company market in the bacteriophage therapy market, which also provides the benefit for the organization to improve their offering for bacteriophage therapy market.

Customization Available: Global Bacteriophages Therapy Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 2 GLOBAL STAPHYLOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 3 GLOBAL ESCHERICHIA COLI IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 GLOBAL PSEUDOMONAS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 GLOBAL STREPTOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 GLOBAL SALMONELLA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 GLOBAL LYTIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 GLOBAL LYSOGENIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 12 GLOBAL STERILE BROTH CULTURE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 GLOBAL WATER-SOLUBLE JELLY BASE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 15 GLOBAL POSTOPERATIVE WOUND INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 GLOBAL INFECTIONS OF SKIN AND NASAL MUCOSA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 GLOBAL BACTERIAL DYSENTERY IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 GLOBAL SUPPURATIVE SKIN INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 GLOBAL LUNG AND PLEURAL INFECTION IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 22 GLOBAL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 GLOBAL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 24 GLOBAL DERMAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 GLOBAL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 GLOBAL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 27 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 29 GLOBAL HOSPITALS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 GLOBAL SPECILIATY CLINICS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 GLOBAL ACADEMIC RESEARCH & INSTITUTES IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 34 GLOBAL DIRECT TENDER IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 GLOBAL THIRD PARTY DISTRIBUTORS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 47 U.S. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 48 U.S. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 U.S. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 50 U.S. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 51 U.S. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 52 U.S. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 53 U.S. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 54 U.S. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 55 U.S. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 CANADA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 57 CANADA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 58 CANADA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 59 CANADA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 60 CANADA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 61 CANADA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 62 CANADA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 63 CANADA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 64 CANADA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 65 EUROPE BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 66 EUROPE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 67 EUROPE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 68 EUROPE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 69 EUROPE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 70 EUROPE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 EUROPE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 EUROPE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 73 EUROPE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 74 EUROPE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 76 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 78 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 79 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 80 GEORGIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 81 GEORGIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 82 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 83 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 84 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 85 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 86 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 87 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 88 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 89 RUSSIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 90 RUSSIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 91 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 93 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 94 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 95 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 96 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 97 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 98 BELGIUM ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 99 BELGIUM PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 100 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 101 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 102 POLAND BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 103 POLAND BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 POLAND BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 105 POLAND BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 106 POLAND BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 107 POLAND ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 108 POLAND PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 109 POLAND BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 110 POLAND BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 111 FRANCE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 112 FRANCE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 113 FRANCE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 114 FRANCE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 115 FRANCE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 116 FRANCE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 117 FRANCE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 118 FRANCE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 119 FRANCE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 120 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 121 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 123 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 124 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 125 NETHERLANDS ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 126 NETHERLANDS PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 127 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 128 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 129 U.K. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 130 U.K. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 131 U.K. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 132 U.K. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 133 U.K. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 134 U.K. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 135 U.K. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 136 U.K. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 137 U.K. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 138 ITALY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 139 ITALY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 140 ITALY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 141 ITALY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 142 ITALY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 143 ITALY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 144 ITALY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 145 ITALY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 146 ITALY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 147 GERMANY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 148 GERMANY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 149 GERMANY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 150 GERMANY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 151 GERMANY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 152 GERMANY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 153 GERMANY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 154 GERMANY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 155 GERMANY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 156 TURKEY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 157 TURKEY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 158 TURKEY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 159 TURKEY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 160 TURKEY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 161 TURKEY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 162 TURKEY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 163 TURKEY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 164 TURKEY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 165 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 166 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 167 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 168 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 169 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 170 SWITZERLAND ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 171 SWITZERLAND PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 172 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 173 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 174 REST OF EUROPE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 175 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 176 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 177 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 178 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 179 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 180 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 181 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 182 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 183 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 184 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 185 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 186 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 187 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 188 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 189 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 190 SOUTH AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 191 SOUTH AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 192 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 193 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 194 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 195 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 196 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 197 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 198 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 199 SAUDI ARABIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 200 SAUDI ARABIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 201 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 202 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 203 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 204 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 205 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 206 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 207 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 208 ISRAEL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 209 ISRAEL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 210 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 211 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 212 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 213 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 214 EGYPT BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 215 EGYPT BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 216 EGYPT BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 217 EGYPT ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 218 EGYPT PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 219 EGYPT BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 220 EGYPT BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 221 REST OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 222 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 223 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 224 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 225 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 226 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 227 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 228 ASIA-PACIFIC ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 229 ASIA-PACIFIC PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 230 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 231 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 232 CHINA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 233 CHINA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 234 CHINA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 235 CHINA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 236 CHINA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 237 CHINA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 238 CHINA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 239 CHINA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 240 CHINA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 241 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 242 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 243 JAPAN BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 244 JAPAN BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 245 JAPAN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 246 JAPAN ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 247 JAPAN PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 248 JAPAN BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 249 JAPAN BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 250 INDIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 251 INDIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 252 INDIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 253 INDIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 254 INDIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 255 INDIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 256 INDIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 257 INDIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 258 INDIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 259 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 260 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 261 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 262 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 263 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 264 AUSTRALIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 265 AUSTRALIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 266 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 267 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 268 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 269 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 270 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 271 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 272 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 273 SOUTH KOREA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 274 SOUTH KOREA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 275 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 276 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 277 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 278 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 279 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 280 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 281 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 282 SINGAPORE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 283 SINGAPORE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 284 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 285 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 286 REST OF ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 287 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 288 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 289 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 290 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 291 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 292 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 293 SOUTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 294 SOUTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 295 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 296 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 297 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 298 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 299 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 300 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 301 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 302 BRAZIL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 303 BRAZIL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 304 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 305 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 306 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 307 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 308 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 309 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 310 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 311 ARGENTINA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 312 ARGENTINA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 313 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 314 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 315 REST OF SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions